Upregulated Dlat has been reported to be associated with poor clinical outcomes in various cancers, including pancreatic adenocarcinoma, liver cancer, and breast cancer via using bioinformatics analysis [32–34]. The gene discussed is DLAT; the disease is pancreatic adenocarcinoma.